Viral surface protein and envelope

Viral surface protein and envelope represent the outermost structural components of a virus, serving as the critical interface for interaction with host cells (NCBI, 2023). These proteins, often glycosylated, are responsible for mediating viral attachment to specific cellular receptors and facilitating the fusion of the viral envelope with the host cell membrane to release the viral genome (Nature Education, 2014). Because they are the first point of contact, they are the primary targets for the host's neutralizing antibodies and are the focus of most vaccine development efforts (PubMed, PMID: 32715666). In clinical pharmacology, these proteins are targeted by various classes of antivirals, including fusion inhibitors like Enfuvirtide and attachment inhibitors like Fostemsavir, which prevent the initiation of the viral life cycle (PubChem). These drugs work by physically blocking the interaction between viral glycoproteins and host receptors or by inhibiting the conformational changes required for membrane fusion. However, the high evolutionary rate of many viruses, particularly RNA viruses, leads to frequent mutations in these surface proteins, necessitating the continuous development of new therapeutics to combat resistance (StatPearls, 2023). Additionally, the diversity of viral surface structures across different families makes the development of broad-spectrum agents targeting these components exceptionally challenging.

Other names

Viral envelope proteinViral surface glycoproteinViral attachment proteinSpike proteinViral coat protein

Inhibition of viral entry by blocking attachment to host receptors, preventing membrane fusion, or inhibiting enzymatic activity required for viral release (NCBI, 2023; StatPearls, 2023).